MedPath

The Effect of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) on Overall Survival of Patients with Relapsed Diffuse Large B-Cell Lymphoma Post-Autologous Stem Cell Transplant

Not Applicable
Conditions
diffuse large B-cell lymphoma
Blood - Haematological diseases
Registration Number
ACTRN12610000803099
Lead Sponsor
Haematology and Oncology Clinics (HOCA) Research Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Patients with histologically-confirmed DLBCL

Must have received CHOP (CHOP 14, CHOP 21) or R-CHOP (R-CHOP 14, R-CHOP 21) chemotherapy as first-line therapy

Must have received an auto-SCT transplant after relapse

Exclusion Criteria

Patients with low-grade lymphoma at presentation or relapse.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath